These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 25506837

  • 1. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
    Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, Hus I, Malm A.
    PLoS One; 2014; 9(12):e114966. PubMed ID: 25506837
    [Abstract] [Full Text] [Related]

  • 2. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T, Kättström M, Hammarlund Y, Roth D, Andersson PO, Svensson M, Nilsson I, Rombo L, Cherif H, Kimby E.
    Vaccine; 2018 Jun 14; 36(25):3701-3707. PubMed ID: 29748028
    [Abstract] [Full Text] [Related]

  • 3. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
    Kättström M, Uggla B, Tina E, Kimby E, Norén T, Athlin S.
    Vaccine; 2023 May 05; 41(19):3128-3136. PubMed ID: 37061372
    [Abstract] [Full Text] [Related]

  • 4. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.
    Lindström V, Aittoniemi J, Salmenniemi U, Käyhty H, Huhtala H, Sinisalo M.
    Hum Vaccin Immunother; 2019 May 05; 15(12):2910-2913. PubMed ID: 31216225
    [Abstract] [Full Text] [Related]

  • 5. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN, McCready W, Ulanova M.
    BMC Immunol; 2019 Nov 12; 20(1):41. PubMed ID: 31718534
    [Abstract] [Full Text] [Related]

  • 6. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.
    Pediatr Blood Cancer; 2015 Aug 12; 62(8):1427-36. PubMed ID: 25810327
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance - Relationship With Selected Immune And Clinical Parameters.
    Pasiarski M, Sosnowska-Pasiarska B, Grywalska E, Stelmach-Gołdyś A, Kowalik A, Góźdź S, Roliński J.
    Clin Interv Aging; 2019 Aug 12; 14():1741-1749. PubMed ID: 31631993
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK.
    Hum Vaccin Immunother; 2019 Aug 12; 15(3):540-548. PubMed ID: 30427749
    [Abstract] [Full Text] [Related]

  • 9. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z, Cox KS, Tang A, Roman J, Fink M, Kaufhold RM, Guan L, Xie A, Boddicker MA, Mcguinness D, Xiao X, Li H, Skinner JM, Verch T, Retzlaff M, Vora KA.
    BMC Infect Dis; 2018 Dec 04; 18(1):613. PubMed ID: 30509199
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3577-84. PubMed ID: 23688526
    [Abstract] [Full Text] [Related]

  • 11. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV, Toh ZQ, Clutterbuck EA, Balloch A, Marimla RA, Tikkanen L, Lamb KE, Bright KJ, Rabuatoka U, Tikoduadua L, Boelsen LK, Dunne EM, Satzke C, Cheung YB, Pollard AJ, Russell FM, Mulholland EK.
    J Allergy Clin Immunol; 2016 Jun 02; 137(6):1772-1779.e11. PubMed ID: 26825000
    [Abstract] [Full Text] [Related]

  • 12. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ, van Westen E, Knol MJ, Jongerius RM, Zancolli M, Goldblatt D, van Gageldonk PG, Tcherniaeva I, Berbers GA, Rots NY.
    PLoS One; 2015 Jun 02; 10(12):e0144739. PubMed ID: 26658902
    [Abstract] [Full Text] [Related]

  • 13. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3594-602. PubMed ID: 23688525
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.
    Clin Vaccine Immunol; 2010 Jun 02; 17(6):1017-26. PubMed ID: 20427630
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Chatfield MD, Lehmann D, Binks M, Chang AB, Carapetis J, Krause V, Andrews R, Snelling T, Skull SA, Licciardi PV, Oguoma VM, Morris PS.
    Lancet Infect Dis; 2022 Sep 02; 22(9):1374-1387. PubMed ID: 35772449
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Kosina P.
    Vaccine; 2017 Sep 12; 35(38):5186-5193. PubMed ID: 28797727
    [Abstract] [Full Text] [Related]

  • 17. The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.
    Robbins A, Bahuaud M, Hentzien M, Maestraggi Q, Barbe C, Giusti D, Le Naour R, Batteux F, Servettaz A.
    Front Immunol; 2021 Sep 12; 12():697128. PubMed ID: 34290713
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3585-93. PubMed ID: 23688527
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F.
    Vaccine; 2019 Feb 14; 37(8):1021-1029. PubMed ID: 30685252
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA.
    Vaccine; 2015 Mar 30; 33(14):1719-25. PubMed ID: 25698485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.